Israeli firms develop targeted approach to tackling cancer-related fibrosis

Baku, November 18, AZERTACIsraeli biotechnology company Eocene Ltd. said it has developed a new formulation of its experimental drug Aramchol designed to target the environment surrounding liver and gastrointestinal cancers, according to TPS-IL. The Givatayim-based company is collaborating with Israeli firm Barcode Nanotech to use lipid nanoparticles to deliver the drug directly to cells that promote tumor-associated fibrosis.The approach aims to reduce fibrosis that can shield tumors from immune responses, potentially improving the effectiveness of immunotherapy and other cancer treatments. The formulation remains in development, with no clinical results reported. Aramchol was previously studied for its effects on liver fibrosis.